Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

GE Healthcare Launches Biacore 4000

By Drug Discovery Trends Editor | February 11, 2010

newsGE Healthcare, a unit of General Electric Company, is launching Biacore 4000, a powerful solution for large-scale, label-free molecular interaction analysis in drug discovery, from early screening to characterization.

Biacore 4000 delivers high quality binding, kinetic, affinity, concentration, and specificity data in both screening assays and detailed characterization studies. The system is designed for large-scale parallel interaction analyses, with the capability to analyze up to 4800 interactions in 24hrs. Biacore 4000 is supported by dedicated software packages for the key drug discovery application areas of small molecule discovery, and antibody screening and characterization, which fully exploit the capabilities of the system.

In combination with the LMW Extension Package software, the Biacore 4000 delivers the sensitivity, throughput and high quality data required for fragment screening, lead selection, and optimization. The system rapidly discriminates between well behaved and promiscuous/atypical binders and presents streamlined, customized data evaluation. Additional kinetic fitting models provide increased flexibility for compound-interaction analysis. Data generated can be easily exported for customized analysis and workflow integration.

The Antibody Extension Package enables Biacore 4000 users to get the best out of their system for antibody analysis applications, saving time and reagents in biotherapeutic development. Dedicated software tools for high throughput kinetic studies and epitope mapping enable rapid identification of promising candidates.  Decision-critical kinetic information is generated twice as fast as with traditional multi-cycle kinetic assays, using the 2-over-2 kinetic approach.

Dr. Paul Leonard, Principal Investigator at the Biomedical Diagnostics Institute, Dublin City University, said: “Providing excellent data quality with unparalleled throughput, Biacore 4000 has become an essential tool in our organisation for the selection of application-tailored antibodies for diagnostic applications.”

Date: February 11, 2010
Source: GE Healthcare


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE